Weight Loss Effect on Circulating Liver Enzymes

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-06-30

Study Completion Date

2016-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To investigate weight loss effect with mild calorie restriction on circulating levels of liver enzymes in nondiabetic and overweight subjects with high visceral fat area \[visceral fat area (VFA) at L4 ≥ 100 cm²\].

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Vigorous- Versus Moderate-intensity Exercise to Reduce Liver Fat in Adults With Obesity and NAFLD

NCT06124456

Obesity NAFLD

RECRUITING NA

Obesity and Nonalcoholic Fatty Liver Disease

NCT00262964

Non-alcoholic Fatty Liver Disease

COMPLETED NA

Effect of Weight Loss and Exercise on Liver and Muscle Fat in Obese Elderly

NCT00779207

Obesity

COMPLETED PHASE3

Effects of Weight Loss on Hepatic and Muscle Lipid Content and on Insulin Sensitivity on Obese Adolescents With NAFLD

NCT00585299

Fatty Liver Insulin Resistance

COMPLETED NA

Intermittent Fasting for NAFLD in Adults

NCT04899102

Fatty Liver Intermittent Fasting Fatty Liver, Nonalcoholic +2 more

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A 12-week randomized, placebo-controlled study was conducted on 80 nondiabetic and overweight subjects with high VFA. The participants divided into two groups: 12-week mild calorie restriction (a 300 kcal/day intake reduction, n=40) or no treatment (control, n=40). The randomization was according to computer-generated block randomization (placebo:test = 1:1). Before and after intervention period, venous blood samples were obtained from the subjects, and biochemical parameters including circulating liver enzymes were measured.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Visceral Fat Liver Dysfunction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control group

No calorie restriction group

Group Type PLACEBO_COMPARATOR

Control group

Intervention Type BEHAVIORAL

The participants who included in control group did not receive any treatment.

Weight loss group

Mild calorie restriction group (300kcal/day intake reduction)

Group Type EXPERIMENTAL

Weight loss group

Intervention Type BEHAVIORAL

The participants who included in weight loss group followed a 12-week weight loss program consisting of a 300 kcal/day reduction of thier usual caloric intakes

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Control group

The participants who included in control group did not receive any treatment.

Intervention Type BEHAVIORAL

Weight loss group

The participants who included in weight loss group followed a 12-week weight loss program consisting of a 300 kcal/day reduction of thier usual caloric intakes

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Able to give informed consent
* 20-60 years old
* Males and females
* Overweight (25.0 kg/m²≤ BMI \<30 kg/m²)
* Absence of pregnancy or breast-feeding
* Stable body weight (body weight change \<1kg for 3 months before screening)
* High visceral fat (VFA) at L4 (VFA at L4 ≥100 cm²)
* Without hypertension, type 2 diabetes, cardiovascular disease, or thyroid disease
* No use medication affecting body weight, energy expenditure, or glucose control for the last 6 months

Exclusion Criteria

* Prior history of Cushing syndrome or malignancy
* Prior history of liver disease including chronic viral hepatitis, autoimmune hepatitis, primary biliary cirrhosis, or drug-induced liver disease
* Excess alcohol intake (based on WHO standard)
* History of intentional reduction in weight in the preceding 6 months

Minimum Eligible Age

20 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes